Oragenics Inc. (OGEN) - Long-Term Debt to Capital Coefficient

As an authoritative developer of intranasal antibiotics, Oragenics, Inc. (OGEN) focuses on creating vaccines capable of inducing mucosal immunity without injections. This price chart illustrates the asset's dynamics, where the current figure is 0.00. The business is currently expanding into a unique segment of concussion therapy drugs, establishing a network of partner clinics in a niche devoid of direct competitors.

This indicator measures the proportion of long-term liabilities within the equity structure to determine the degree of financial leverage. It allows investors to assess the company's resilience to long-term credit risks and its discipline in managing borrowed capital. For Oragenics, Inc. (OGEN), this balance is critical when financing the development of patented proteins and establishing a closed-loop supply chain. The trend in the long-term debt-to-equity ratio reflects the business's ability to scale its biopharmaceutical ecosystem without incurring an excessive debt burden.